Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases. The company's lead product candidate, Descartes-08, is in Phase 3 development for myasthenia gravis (MG). The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $452 | $387 | $1,850 | $39,672 |
| Net Loss | $(35,902) | $(24,183) | $(37,726) | $(67,171) |
| Diluted EPS | $(1.38) | $(1.13) | $(1.45) | $(4.61) |
| Operating Expenses | $21,518 | $17,962 | $66,616 | $56,838 |
| Cash & Equivalents (Balance Sheet) | $143,384 (as of Sept 30, 2025) | |||
| Total Cash, Equivalents & Restricted Cash | $145,119 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(729,797) (as of Sept 30, 2025) |
Liquidity: Management believes existing cash resources will fund operations for at least the next 12 months. The company has no product revenue and relies on grants, collaborations, and equity financings.
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenue dropped 95% to $1.85 million from $39.7 million in the prior year. This decrease is primarily due to the absence of a $30.0 million milestone payment recognized in 2024 under the Sobi License and the termination of the Astellas Agreement in June 2024.
- Net Loss Improvement (9M): Net loss decreased 44% to $37.7 million from $67.2 million. This improvement was driven by a $70.6 million favorable swing in the fair value of the Contingent Value Right (CVR) liability (a gain of $18.7 million in 2025 vs. a loss of $51.9 million in 2024).
- Operating Expense Increase: Research and Development (R&D) expenses increased 28% to $43.3 million for the nine months ended September 30, 2025, driven by the ongoing Phase 3 AURORA trial for Descartes-08 and headcount growth. This was partially offset by the cessation of legacy Selecta program expenses.
- Cash Burn: Net cash used in operating activities increased to $56.2 million for the nine months ended September 30, 2025, compared to $16.7 million in the prior year period.
Outlook, Risks, and Unusual Items
- Contingent Value Rights (CVR): The company holds a significant CVR liability of $369.0 million. Under the CVR Agreement, 100% of milestone payments and royalties from the Sobi License and legacy asset monetization must be distributed to CVR holders. The company has no obligation to fund this liability from its own cash reserves.
- Financing History: In July 2024, the company completed a private placement raising approximately $130.0 million. An "at-the-market" offering program was established in December 2024, though no shares were sold in the first nine months of 2025.
- Key Risks:
- Dependence on third-party collaborators (e.g., Sobi) for funding and commercialization of legacy assets.
- Uncertainty regarding the timing and success of clinical trials for Descartes-08.
- Need for additional capital to sustain operations beyond the next 12 months; future financing may be dilutive.
- Volatility in the fair value of the CVR and warrant liabilities impacting reported net income/loss.
- Unusual Items: The financial results are heavily influenced by non-cash fair value adjustments related to the CVR liability and warrant liabilities. The company recognized a $16.9 million loss on the CVR liability in Q3 2025, contrasting with a $18.7 million gain for the full nine-month period.
Investor Verification Checklist
- Cash Runway: Verify the specific monthly burn rate and confirm the 12-month liquidity estimate given the high operating cash usage ($56.2M in 9 months).
- CVR Liability Impact: Assess the sensitivity of the $369 million CVR liability to changes in the Sobi License milestone probabilities and interest rates.
- Phase 3 Trial Status: Confirm enrollment progress and interim data timelines for the Descartes-08 AURORA trial, which is the primary driver of R&D spend.
- Collaboration Revenue: Monitor the status of the Sobi License for SEL-212 (gout) to understand potential future cash inflows that would be immediately distributed to CVR holders.
- Stock-Based Compensation: Review the $8.4 million in stock-based compensation expense for the nine months ended September 30, 2025, and its impact on future dilution.